CalciMedica(CALC) - 2024 Q1 - Quarterly Results

Exhibit 99.1 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024 with data expected in 2025 Cash position expected to fund operations into 2H 2025 Recent Clinical and Preclinical Updates and Anticipated Milestones: • Phase 2 KOURAGE trial initiation underway: In February 2024, CalciMedica received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for Auxora to be evaluated in a Phase 2 ...